Supplementary Data 1 from Clinical and Biomarker Analysis of a Phase I/II Study of PDR001 Plus Imatinib for Advanced Treatment-Refractory Gastrointestinal Stromal Tumors | Synapse
July 1, 2024Open Access
Supplementary Data 1 from Clinical and Biomarker Analysis of a Phase I/II Study of PDR001 Plus Imatinib for Advanced Treatment-Refractory Gastrointestinal Stromal Tumors
Key Points
Key points are not available for this paper at this time.